← Leaderboards
John C Kappes
Birmingham Va Medical Center
$5,331,946
Attributed
$8,086,913
Total exposure
12
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,086,913 · 10
VA$0 · 2
By mechanism
R01$5,050,611 · 3
P30$2,038,265 · 4
R21$810,787 · 2
R41$187,250 · 1
I01$0 · 2
Top collaborators
- David T Evans6 shared
- Andres Finzi6 shared
- Christina Ochsenbauer2 shared
Most similar at Birmingham Va Medical Center
Same institution · by research overlap
- Lisa M Curtis$766,566
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusHiv-1Transmission ProcessAffectPredispositionCellsInfectionMucous MembraneHuman ResourcesServicesAcquired Immunodeficiency SyndromeInnovationPhysiologicalExposure ToSiteTrainingMolecularAids/Hiv ProblemInvestigationViralDoseMolecular CloningFemaleResearch Personnel
Grant awards (39)
Elucidating mechanisms of HIV-1 mucosal transmission$0
I01 · FY2025 · VA · contact PI
The effects of masculinizing gender-affirming hormone therapy for transgender men on susceptibility to HIV-1 infection modelled ex vivo in cervical mucosal tissue$185,625
R21 · FY2024 · AI
Elucidating mechanisms of HIV-1 mucosal transmission$0
I01 · FY2024 · VA · contact PI
Assessing ADCC and Fc-mediated Protection against HIV$767,088
R01 · FY2023 · AI
The effects of masculinizing gender-affirming hormone therapy for transgender men on susceptibility to HIV-1 infection modelled ex vivo in cervical mucosal tissue$222,750
R21 · FY2023 · AI
Assessing ADCC and Fc-mediated Protection against HIV$185,625
R01 · FY2023 · AI
Elucidating mechanisms of HIV-1 mucosal transmission$0
I01 · FY2023 · VA · contact PI
Assessing ADCC and Fc-mediated Protection against HIV$767,578
R01 · FY2022 · AI
Elucidating mechanisms of HIV-1 mucosal transmission$0
I01 · FY2022 · VA · contact PI
Assessing ADCC and Fc-mediated Protection against HIV$764,967
R01 · FY2021 · AI
Elucidating mechanisms of HIV-1 mucosal transmission$0
I01 · FY2021 · VA · contact PI
Assessing ADCC and Fc-mediated Protection against HIV$656,716
R01 · FY2020 · AI
Elucidating mechanisms of HIV-1 mucosal transmission$0
I01 · FY2020 · VA · contact PI
Assessing ADCC and Fc-mediated Protection against HIV$684,196
R01 · FY2019 · AI
Analysis of human uterine mucosal cells as targets of HIV-1 infection$0
I01 · FY2018 · VA · contact PI
Virology Core$112,032
P30 · FY2017 · AI · contact PI
Analysis of human uterine mucosal cells as targets of HIV-1 infection$0
I01 · FY2017 · VA · contact PI
Early determinants of HIV 1 acquisition in cervicovaginal mucosa$181,912
R21 · FY2016 · HD · contact PI
Virology Core$122,781
P30 · FY2016 · AI · contact PI
Analysis of human uterine mucosal cells as targets of HIV-1 infection$0
I01 · FY2016 · VA · contact PI
Early determinants of HIV 1 acquisition in cervicovaginal mucosa$220,500
R21 · FY2015 · HD · contact PI
Virology Core$103,441
P30 · FY2015 · AI · contact PI
Virology Core$125,951
P30 · FY2014 · AI · contact PI
Virology$125,890
P30 · FY2013 · AI · contact PI
Virology$361,910
P30 · FY2012 · AI · contact PI
Virology$334,339
P30 · FY2011 · AI · contact PI
Virology$321,128
P30 · FY2010 · AI · contact PI
Virology$186,004
P30 · FY2009 · AI · contact PI
Virology$102,031
P30 · FY2008 · AI · contact PI
ANALYSIS OF INTEGRASE IN REVERSE TRANSCRIPTION$251,125
R01 · FY2003 · AI
Single cycle reporter assay for quantifying HIV-1 Nab$187,250
R41 · FY2003 · AI
ANALYSIS OF INTEGRASE IN REVERSE TRANSCRIPTION$251,125
R01 · FY2002 · AI
CORE--CENTRAL VIRUS CULTURE$0
P30 · FY2002 · AI
ANALYSIS OF INTEGRASE IN REVERSE TRANSCRIPTION$251,125
R01 · FY2001 · AI
CORE--CENTRAL VIRUS CULTURE$0
P30 · FY2001 · AI
CORE--CENTRAL VIRUS CULTURE$0
P30 · FY2001 · AI
ANALYSIS OF INTEGRASE IN REVERSE TRANSCRIPTION$244,339
R01 · FY2000 · AI
TRANSCOMPLEMENTATION SYSTEM TO STUDY PROVIRUS SYNTHESIS$226,727
R01 · FY2000 · CA
CORE--CENTRAL VIRUS CULTURE$142,758
P30 · FY2000 · AI